Company Filing History:
Years Active: 1988-1996
Title: Innovations and Patents of Benjamin Greenman
Introduction
Benjamin Greenman, an inventive mind based in Rehovot, Israel, has made significant contributions to the field of biotechnology. With a robust portfolio comprising five patents, Greenman's work predominantly focuses on methods of producing and purifying pharmacologically significant proteins and polysaccharides.
Latest Patents
Among his latest inventions is a method for the production and purification of recombinant Apolipoprotein E (ApoE). This innovative approach involves techniques for purifying human ApoE or its analogs derived from recombinant bacterial cells, minimizing protein aggregation and degradation throughout the purification process. The method includes the strategic addition of neutralized fatty acids during cell disruption, alongside the application of non-ionic detergents during purification. Furthermore, it outlines a technique to enhance ApoE production in bacterial hosts through the augmentation of culture mediums with neutralized fatty acids, fatty acid precursors, triglycerides, triglyceride precursors, or acetate. The potential pharmaceutical and diagnostic applications of the ApoE analog are significant and noteworthy.
Another of Greenman’s key inventions involves the production of high molecular weight sodium hyaluronate. He has developed a novel mutant microorganism, Streptococcus zooepidemicus HA-116 ATCC 39920, capable of producing large quantities of high molecular weight hyaluronic acid. This invention encompasses a method for cultivating these microorganisms under optimal conditions, including maintaining a constant concentration of sugar components and magnesium ions in the nutrient medium. The resultant sodium hyaluronate is distinguished by its purity, featuring an absence of pyrogenicity and skin irritation.
Career Highlights
Benjamin Greenman has established his professional career at Bio-Technology General Corporation, where he has contributed to groundbreaking advancements in biopharmaceuticals. His inventions have propelled the company to the forefront of biotechnology research and development.
Collaborations
Throughout his career, Greenman has worked closely with esteemed colleagues such as Abraham Nimrod and Dov Kanner. Their collaborative efforts have been instrumental in advancing bioengineering techniques and facilitating innovative solutions in the biotechnology sector.
Conclusion
Benjamin Greenman stands as a prolific inventor whose cutting-edge work in biotechnology continues to have a profound impact on the field. With five patents to his name, his innovative spirit and collaborative endeavors with fellow researchers underscore his commitment to advancing medical and pharmaceutical sciences. As he continues to explore new horizons in biotechnology, his contributions remain pivotal for future advancements in health and medicine.